Color Additives: Current Thoughts on Biological Safety

13
Color Additives: Current Thoughts on Biological Safety Don R. Pohl Senior Principal Scientist NAMSA

description

Color Additives: Current Thoughts on Biological Safety, also titled Colorants: Current Thoughts and Recommendations for Biological Safety, reviews the many concerns around color additives as well as different types of testing that should be used.

Transcript of Color Additives: Current Thoughts on Biological Safety

Page 1: Color Additives: Current Thoughts on Biological Safety

Color Additives: Current Thoughts on Biological Safety

Don R. Pohl

Senior Principal Scientist

NAMSA

Page 2: Color Additives: Current Thoughts on Biological Safety

2

Overview Basis for Concern - Why does it appear the FDA

is asking about colorants? Significance of listing colorants in CFR Role of biocompatibility Role of vendor supplied information Role of extractables testing and risk assessment

Page 3: Color Additives: Current Thoughts on Biological Safety

3

Basis for Concern

Page 4: Color Additives: Current Thoughts on Biological Safety

4

There are three key items that help answer why colorants are a present concern

Information from FDA website FDA comments from deficiency statements and discussions with

reviewers Draft Guidance released April 23, 2013 regarding replacement for

Blue Book Memorandum #G95-1

Page 5: Color Additives: Current Thoughts on Biological Safety

5

FDA Website The following are some of the documents on FDA’s

website that discuss the use of colorants: Food, Drug and Cosmetic Act Code of Federal Regulations FDA Public Health Advisory

Page 6: Color Additives: Current Thoughts on Biological Safety

6

Role of Biocompatibility

Page 7: Color Additives: Current Thoughts on Biological Safety

7

“Complete” biocompatibility testing of final devices are not enough in all cases

Page 8: Color Additives: Current Thoughts on Biological Safety

8

Depending on information available, more biological data may be needed: genotoxicity, reproductive toxicity and/or carcinogenicity. ADME mentioned as well

Vendor biocompatibility data may be useful, but not enough to answer everything

Biocompatibility testing alone may not be sensitive enough to address the issue

Page 9: Color Additives: Current Thoughts on Biological Safety

9

Role of Vendor Supplied Information

Page 10: Color Additives: Current Thoughts on Biological Safety

10

Data from vendor of the color additive is imperative

Identity of each specific color additive is needed in the device

Information allows risk of the color additive to be initially assessed

Lack of identity does not allow for assessment to be performed as risks cannot be established

Page 11: Color Additives: Current Thoughts on Biological Safety

11

Role of Extractables Testing and Risk Assessment

Page 12: Color Additives: Current Thoughts on Biological Safety

12

Risk Assessment can play two roles in this process Initial evaluation of what is known If exposure is possible, can evaluate if 100% is

available what is the risk Extractables Testing

Becomes the source of additional information FDA has commented on several approaches to

extractables testing of color additives